Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Fort Lauderdale, FL
NPI: 1407180615Primary Practice Location
HOLY CROSS HOSPITAL
4725 N Federal Hwy, Fort Lauderdale, FL
Primary Employer
Holy Cross Medical Group
holy-cross.com
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2009 - 2027
GA State Medical License
2009 - 2011
OH State Medical License
2001 - 2011
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
National Institutes of Health Clinical Center
Fellowship • Hematology and Medical Oncology
2006 - 2009
Jewish Hospital of Cincinnati
Residency • Internal Medicine
2001 - 2004
Nanjing University Of Traditional Chinese Medicine
Medical School
Until 1992
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 185 | 274 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 134 | 302 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 89 | 114 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 72 | 72 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 51 | 70 |
Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia.
'Case Report and Review of 7 Similar Cases in the Literature: Cutaneous Sarcoidosis
Authors: Kimberly Hull
Journal: J Immunother
Case Report and Review of 7 Similar Cases in the Literature: Cutaneous Sarcoidosis as Side Effect of Pembrolizumab Plus Chemotherapy in Stage IV Squamous Cell Carcinoma of Lung.
Authors: Kimberly Hull
Publication Date: 2020-05-18
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Placebo, DRUG: Carboplatin, DRUG: Cisplatin, DRUG: Paclitaxel, DRUG: Etoposide, DRUG: Pemetrexed, DRUG: Durvalumab, RADIATION: Intensity Modulated Radiation Therapy (IMRT), DRUG: M7824
Lead Sponsor: PharmaMar
Intervention / Treatment: DRUG: Topotecan, DRUG: Cyclophosphamide (CTX), DRUG: Lurbinectedin (PM01183), DRUG: Doxorubicin (DOX), DRUG: Vincristine (VCR)
Lead Sponsor: Calithera Biosciences, Inc
Intervention / Treatment: DRUG: Placebo, DRUG: Telaglenastat, DRUG: Carboplatin Chemotherapy, DRUG: Pemetrexed Chemotherapy, BIOLOGICAL: Pembrolizumab Immunotherapy, DIETARY_SUPPLEMENT: Folic acid 400 -1000 μg, DIETARY_SUPPLEMENT: Vitamin B12 1000 μg, DRUG: Dexamethasone 4 mg
